Notice of AGM

Ondine Biomedical Inc. (AIM: OBI) announces that the notice of the Company's 2026 Annual General Meeting ("AGM") and the associated form of proxy have been published today on the Company's website at https://ondinebio.com/investors/reports-documentation/.

Printed copies of the notice of AGM and form of proxy will be posted today to registered shareholders who have elected to receive paper communications.

The Company's AGM will be held virtually at 16:00 BST (08:00 Pacific time) on 30 June 2026. Details of how to access the meeting are contained in the notice of AGM.

The items of business to be voted on at the Meeting are:

• the re-election of Carolyn Cross, Nicolas G. Loebel, Jean Charest, Jean Duvall, Junaid Bajwa, and Margaret Shaw as directors of the Company to hold office until the 2027 annual meeting of shareholders or until their successors are elected and qualified, subject to earlier resignation or removal.
• the re-appointment of PricewaterhouseCoopers LLP, Chartered Professional Accountants, as auditors for the Company for the ensuing year; and
• to transact such other business as may properly come before the Meeting.

The result of the AGM will be announced after its conclusion and published on the Company's website.

Ondine Biomedical Inc.

About Ondine Biomedical Inc.

U.S. Regulatory Status Disclaimer

Steriwave® is CE-marked in Europe and is approved for nasal decolonisation in Canada, the United Kingdom, Australia, and Mexico. In the United States, Steriwave has been granted Qualified Infectious Disease Product (QIDP) designation and Fast Track status by the U.S. Food and Drug Administration (FDA). It is currently undergoing clinical trials in the United States to support regulatory approval and is limited by United States law to investigational use only. It is not commercially available for sale or clinical use in the United States.